Affiliation: Kings College London
Location: London, United Kingdom
Dr. Sophia Karagiannis is a translational cancer immunologist specialising in antibody therapies for melanoma, ovarian and breast carcinomas who has undertaken discovery and development of immunotherapeutics in academic and biotechnology environments. She has a track record on evaluating the tumour-targeting mechanisms of IgE antibodies and Th2 responses in cancer and has led studies on monoclonal antibodies of the IgG and IgE classes for the treatment of solid tumours since 1998. These have yielded the first IgE antibody therapeutic candidate for the treatment of cancer, presently in development for clinical trials in patients with FRα+ carcinomas by her team at Kings College London in collaboration with Cancer Research UK.
Since 2007 she heads her own King
Lacy KE, Karagiannis SN, Nestle FO, Immunotherapy for melanoma. Expert Rev Dermatol, 7(1): 51-68, DOI:10.1586/edm.11.80, 2012.
Karagiannis SN, Nestle FO, Gould HJ. IgE interacts with potent effector cells against tumors: ADCC and ADCP, in
- Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivityS M Rudman
NIHR Biomedical Research Centre at Guy s and St Thomas s Hospitals and King s College London, Cutaneous Medicine and Immunotherapy Unit, St John s Institute of Dermatology, Division of Genetics and Molecular Medicine, King s College London School of Medicine, Guy s Hospital, King s College London, London, UK
Clin Exp Allergy 41:1400-13. 2011....
- IgG4 Characteristics and Functions in Cancer ImmunitySilvia Crescioli
St John s Institute of Dermatology, Division of Genetics and Molecular Medicine Faculty of Life Sciences and Medicine, King s College London, London, UK
Curr Allergy Asthma Rep 16:7. 2016..We discuss the inflammatory conditions in tumors that support IgG4, the emerging and proposed mechanisms by which IgG4 may contribute to tumor-associated escape from immune surveillance and implications for cancer immunotherapy. ..
- IgG4 antibodies and cancer-associated inflammation: Insights into a novel mechanism of immune escape.Panagiotis Karagiannis
Cutaneous Medicine and Immunotherapy Unit St John s Institute of Dermatology Division of Genetics and Molecular Medicine NIHR Biomedical Research Centre at Guy s and St Thomas s Hospitals and King s College London London, UK
Oncoimmunology 2:e24889. 2013..These previously unappreciated mechanisms of immune escape may constitute promising targets for the development of novel anticancer immunotherapies...
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cellsPanagiotis Karagiannis
Cutaneous Medicine and Immunotherapy Unit, St John s Institute of Dermatology, Division of Genetics and Molecular Medicine, King s College London School of Medicine, Guy s Tower, Guy s Hospital, London, UK
Cancer Immunol Immunother 58:915-30. 2009..These functional characteristics of trastuzumab IgE, some distinct from those of trastuzumab, indicate its potential to complement or improve upon the existing clinical benefits of trastuzumab...
- Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosisMarguerite Bracher
Randall Division of Cell and Molecular Biophysics, Kings College London, New Hunts House, London, United Kingdom
J Immunol Methods 323:160-71. 2007..We illustrate the new method by analysing human monocyte-mediated cytotoxic and phagocytic cell killing of IGROV1 ovarian tumour cells by the ovarian tumour antigen-specific anti-folate binding protein monoclonal antibody, MOv18 IgE...
- Toward prediction of immune mechanisms and design of immunotherapies in melanomaSophia Tsoka
Centre for Bioinformatics, Department of Informatics, School of Natural and Mathematical Sciences, King s College London, United Kingdom
Crit Rev Biomed Eng 40:279-94. 2012..We propose that efforts in this direction may realize the potential of personalized medicine and facilitate development of the next generation of efficacious tools to treat patients...
- Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort studyMieke Van Hemelrijck
Cancer Epidemiology Group, King s College London, London, UK
Cancer Causes Control 21:1657-67. 2010..Our findings suggest the need for prospective studies studying IgE and cancer. Measurements of IgE should be combined with other information, e.g., bio-banked samples containing other key immunological discriminators...
- Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammationChung Ching Chu
St John s Institute of Dermatology, King s College London and National Institutes for Health Research Biomedical Research Centre, London, UK
J Exp Med 209:935-45. 2012..Finally, VitD3-induced CD141(+) DDC-like cells have potential clinical use for their capacity to induce immune tolerance...
- Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodiesAmy E Gilbert
Cutaneous Medicine and Immunotherapy Unit, Division of Genetics and Molecular Medicine, NIHR Biomedical Research Centre at Guy s and St Thomas s Hospitals and King s College London, King s College London School of Medicine, St John s Institute of Dermatology, Guy s Hospital, King s College London, London, United Kingdom
PLoS ONE 6:e19330. 2011....
- Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cellsSophia N Karagiannis
Randall Division of Cell and Molecular Biophysics, King s College London, Room 3 8, New Hunt s House, Guy s Campus, St Thomas s Street, London, SE1 1UL, UK
Cancer Immunol Immunother 57:247-63. 2008..Harnessing IgE receptors to target tumor cells suggests the potential of tumor-specific IgE antibodies to activate effector cells in immunotherapy of ovarian cancer...
- IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cellsSophia N Karagiannis
Randall Division of Cell and Molecular Biophysics, New Hunt s House, King s College London, Guy s Campus, London, United Kingdom
J Immunol 179:2832-43. 2007..These results demonstrate that IgE Abs can engage cell surface IgE receptors and activate effector cells against ovarian tumor cells. Our findings offer a framework for an improved immunotherapeutic strategy for combating solid tumors...
- Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical applicationSophia N Karagiannis
NIHR Biomedical Research Centre at Guy s and St Thomas s Hospitals and King s College London, London, UK
Cancer Immunol Immunother 61:1547-64. 2012..On-going efficacy, safety evaluations and future first-in-man clinical studies of IgE therapeutics constitute key metrics for this concept, providing new scope for antibody immunotherapies for solid tumours...
- Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cellsSophia N Karagiannis
The Randall Centre, King s College London, London, GB
Eur J Immunol 33:1030-40. 2003..We observed phagocytosis of tumor cells by the monocytes in vitro. Our results suggest that tumor-specific IgE antibodies may be exploited for immunotherapy of cancer...